Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Clinical Trials Using Mycophenolate Mofetil

Review the clinical trials studying mycophenolate mofetil on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 48

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 30 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 30 locations
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Location: 4 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
Fludarabine and Intermediate-dose Total Body Irradiation Conditioning plus Post-Transplant Cyclophosphamide for the Treatment of Patients Undergoing Allogeneic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: 3 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Status: Active
Location: 2 locations
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Status: Active
Location: 2 locations
Pre-Transplant Thiotepa-based Conditioning and De-Escalated Post-Transplant Cyclophosphamide for the Treatment of Patients with Leukemia, Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Status: Active
Location: 2 locations
T Cells (EAGD T-Cells) after Stem Cell Transplantation and Post-transplant Cyclophosphamide for the Treatment of Blood Cancers
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Post-Transplant Cyclophosphamide for the Prevention of Graft Versus Host Disease in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning for Hematological Diseases
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Allogeneic Hematopoietic Stem Cell Transplantation Using Treosulfan Conditioning with Post-Transplant Cyclophosphamide for the Treatment of Hematologic Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California